GSK PLC SP. ADR/2 NEW (GS70) — Cash Flow Reinvestment Rate
GSK PLC SP. ADR/2 NEW (GS70) has a Cash Flow Reinvestment Rate of 0.24x as of June 2026, reinvesting €653.00 Million (capex €653.00 Million ) from operating cash flow of €2.69 Billion. See GSK PLC SP. ADR/2 NEW free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
GSK PLC SP. ADR/2 NEW Cash Flow Reinvestment Rate (2021–2025)
Historical reinvestment intensity for GSK PLC SP. ADR/2 NEW across 5 annual periods. For the full cash flow conversion analysis, see GSK PLC SP. ADR/2 NEW cash flow conversion.
Annual Cash Flow Reinvestment Rate for GSK PLC SP. ADR/2 NEW (2021–2025)
Year-by-year capital reinvestment analysis for GSK PLC SP. ADR/2 NEW. See GSK PLC SP. ADR/2 NEW (GS70) flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.39x | €3.00 Billion | €7.74 Billion | €2.98 Billion | ▼ -15.5% |
| 2024 | 0.46x | €3.00 Billion | €6.55 Billion | €2.98 Billion | ▲ +28.4% |
| 2023 | 0.36x | €2.42 Billion | €6.77 Billion | €2.34 Billion | ▲ +17.0% |
| 2022 | 0.31x | €2.26 Billion | €7.40 Billion | €2.26 Billion | ▼ -9.2% |
| 2021 | 0.34x | €2.67 Billion | €7.95 Billion | €2.65 Billion | — |